Pamidronate Infusions as Single-agent Therapy for Bone Metastases: A Phase II Trial in Patients with Breast Cancer

By Tyrrell C.T.   Bruning P.F.   May-Levin F.   Rose C.   Mauriac L.   Soukop M.   Ford J.M.  

European Journal of Cancer, Vol. 31, Iss. 12, 1995-11 ,pp. : 1976-1980

Elsevier

Access to resources Recommend Favorite

O⁶-benzylguanine and BCNU in multiple myeloma: a phase II trial

By Batts Eric   Maisel Christopher   Kane Donna   Liu Lili   Fu Pingfu   O’Brien Timothy   Remick Scot   Bahlis Nizar   Gerson Stanton  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 415-421

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: A phase 2 trial

By Abou-Jawde Rony   Reed Janice   Kelly Megan   Walker Esteban   Andresen Steven   Baz Rachid   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 263-272

Humana Press, Inc

Access to resources Recommend Favorite

Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma

By Chiou Tzeon-Jye   Wang Teng-Hsu   Chao Tsu-Yi   Lin Sheng-Fung   Tang Jih-Luh   Chen Tsai-Yun   Chang Ming-Chih   Hsueh Erh-Jung   Chen Po-Min  

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 140-147

Informa Healthcare

Access to resources Recommend Favorite

Phase II Trial of rhIL-6 (Interleukin-6) Prior to and Concurrently with VAD (Vincristine, Doxorubicin and Dexamethasone) Chemotherapy for Patients with Multiple Myeloma

By Young R.I.   Ranson M.   Chang J.   Lord B.   Testa N.   Scarffe J.H.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 307-311

Elsevier

Access to resources Recommend Favorite